1. Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1.
- Author
-
Bandekar SJ, Chen CL, Ravala SK, Cash JN, Avramova LV, Zhalnina MV, Gutkind JS, Li S, and Tesmer JJG
- Subjects
- Animals, Cryoelectron Microscopy, Guanine Nucleotide Exchange Factors metabolism, Humans, Protein Binding, Protein Serine-Threonine Kinases metabolism, Rho Guanine Nucleotide Exchange Factors metabolism, Signal Transduction, Uveal Neoplasms, rac1 GTP-Binding Protein genetics, rac1 GTP-Binding Protein metabolism, Guanine Nucleotide Exchange Factors chemistry, Protein Serine-Threonine Kinases chemistry, Rho Guanine Nucleotide Exchange Factors chemistry
- Abstract
Trio is a large and highly conserved metazoan signaling scaffold that contains two Dbl family guanine nucleotide exchange factor (GEF) modules, TrioN and TrioC, selective for Rac and RhoA GTPases, respectively. The GEF activities of TrioN and TrioC are implicated in several cancers, especially uveal melanoma. However, little is known about how these modules operate in the context of larger fragments of Trio. Here we show via negative stain electron microscopy that the N-terminal region of Trio is extended and could thus serve as a rigid spacer between the N-terminal putative lipid-binding domain and TrioN, whereas the C-terminal half of Trio seems globular. We found that regions C-terminal to TrioN enhance its Rac1 GEF activity and thus could play a regulatory role. We went on to characterize a minimal, well-behaved Trio fragment with enhanced activity, Trio
1284 - 1959 , in complex with Rac1 using cryo-electron microscopy and hydrogen-deuterium exchange mass spectrometry and found that the region conferring enhanced activity is disordered. Deletion of two different strongly conserved motifs in this region eliminated this enhancement, suggesting that they form transient intramolecular interactions that promote GEF activity. Because Dbl family RhoGEF modules have been challenging to directly target with small molecules, characterization of accessory Trio domains such as these may provide alternate routes for the development of therapeutics that inhibit Trio activity in human cancer., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF